Effectiveness of pertussis vaccination in New South Wales, Australia, 1996-1998

被引：23

作者：

Siranda Torvaldsen

Judy M. Simpson

Peter B. McIntyre

机构：

[1] Natl. Ctr. Immun. Res./Survlnc., University of Sydney, Sydney, NSW

[2] Department of Public Health, University of Sydney, Sydney, NSW

[3] Natl. Ctr. Immunisation Res./Surv., Children's Hospital at Westmead, Westmead, NSW 2145

来源：

European Journal of Epidemiology | 2003年 / 18卷 / 1期

关键词：

Pertussis; Screening method; Vaccine effectiveness; Whole-cell pertussis vaccine;

D O I：

10.1023/A:1022588118030

中图分类号：

学科分类号：

摘要：

Pertussis notifications have increased over the past decade in Australia and other industrialised countries. This study estimates the effectiveness of pertussis vaccination in one Australian State (New South Wales, NSW) among children aged less than 14 years, during a period when an Australian wholecell pertussis vaccine was in routine use. Cases notified with pertussis between 1996 and 1998 and pertussis vaccine coverage estimates from the Australian Childhood Immunisation Register were used. Vaccine effectiveness (VE) was calculated using the screening method, with adjustment for age group, year of disease onset and area of residence. VE was highest (91%) in the youngest age group (8-23 months) and lowest (78%) in the oldest age group (9-13 years). Pertussis vaccination is highly effective at preventing pertussis in NSW children, as measured by notified cases. Ongoing monitoring will be important to evaluate VE following Australia's change to an acellular vaccine based program.

引用

页码：63 / 69

页数：6

共 22 条

[1]

McIntyre P., Amin J., Gidding H., Et al., Vaccine preventable diseases and vaccination coverage in Australia, 1993-1998, Commun Dis Intell, 24, (2000)

[2]

De Melker H.E., Schellekens J.F.P., Neppeelenbroek S.E., Mooi F.R., Rumke H.C., Conyn-Van Spaendonck M.A.E., Reemergence of pertussis in the highly vaccinated population of the Netherlands: Observations on surveillance data, Emerg Infect Dis, 6, pp. 348-357, (2000)

[3]

Halperin S.A., Bortolussi R., MacLean D., Chisholm N., Persistence of pertussis in an immunized population: Results of the Nova Scotia enhanced pertussis surveillance program, J Pediatr, 115, pp. 686-693, (1989)

[4]

Van Buynder P.G., Owen D., Vurdien J.E., Andrews N.J., Mathews R.C., Miller E., Bordetella pertussis surveillance in England and Wales: 1995-1997, Epidemiol Infect, 123, pp. 403-411, (1999)

[5]

Ramsay M., Farrington C., Miller E., Age-specific efficacy of pertussis vaccine during epidemic and non-epidemic periods, Epidemiol Infect, 111, pp. 41-48, (1993)

[6]

Guris D., Strebel P.M., Tachdjian R., Bardenheier B., Wharton M., Hadler S.C., Effectiveness of the pertussis vaccination program as determined by use of the screening method: United States, 1992-1994, J Infect Dis, 176, pp. 456-463, (1997)

[7]

Blakely T., Mansoor O., Baker M., The 1996 pertussis epidemic in New Zealand: Vaccine effectiveness, N Z Med J, 112, pp. 118-120, (1999)

[8]

Baron S., Njamkepo E., Grimprel E., Et al., Epidemiology of pertussis in French hospitals in 1993 and 1994: Thirty years after a routine use of vaccination, Pediatr Infect Dis J, 17, pp. 412-418, (1998)

[9]

Herceg A., The decline of Haemophilus influenzae type b disease in Australia, Commun Dis Intell, 21, pp. 173-176, (1997)

[10]

Surveillance Case Definitions, (1994)

← 1 2 3 →